Arkadios Wealth Advisors raised its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST – Get Rating) by 8.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,389 shares of the medical instruments supplier’s stock after acquiring an additional 104 shares during the quarter. Arkadios Wealth Advisors’ holdings in West Pharmaceutical Services were worth $342,000 at the end of the most recent quarter.
Other large investors have also recently added to or reduced their stakes in the company. CX Institutional acquired a new stake in shares of West Pharmaceutical Services during the second quarter worth $28,000. Householder Group Estate & Retirement Specialist LLC acquired a new stake in shares of West Pharmaceutical Services during the third quarter worth $36,000. Allworth Financial LP raised its holdings in shares of West Pharmaceutical Services by 70.8% during the second quarter. Allworth Financial LP now owns 123 shares of the medical instruments supplier’s stock worth $37,000 after purchasing an additional 51 shares during the period. Private Trust Co. NA raised its holdings in shares of West Pharmaceutical Services by 194.6% during the third quarter. Private Trust Co. NA now owns 165 shares of the medical instruments supplier’s stock worth $41,000 after purchasing an additional 109 shares during the period. Finally, Glassman Wealth Services raised its holdings in shares of West Pharmaceutical Services by 57.0% during the second quarter. Glassman Wealth Services now owns 146 shares of the medical instruments supplier’s stock worth $44,000 after purchasing an additional 53 shares during the period. 91.51% of the stock is currently owned by institutional investors.
Insider Buying and Selling at West Pharmaceutical Services
In other West Pharmaceutical Services news, CEO Eric Mark Green sold 44,000 shares of the firm’s stock in a transaction dated Monday, December 5th. The shares were sold at an average price of $238.99, for a total transaction of $10,515,560.00. Following the transaction, the chief executive officer now owns 114,922 shares of the company’s stock, valued at approximately $27,465,208.78. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.60% of the stock is owned by corporate insiders.
West Pharmaceutical Services Stock Down 1.5 %
West Pharmaceutical Services stock opened at $235.35 on Friday. The stock has a market cap of $17.42 billion, a price-to-earnings ratio of 28.39, a PEG ratio of 1.94 and a beta of 1.14. The company has a current ratio of 3.80, a quick ratio of 2.89 and a debt-to-equity ratio of 0.08. The company’s 50-day moving average price is $233.26 and its two-hundred day moving average price is $272.83. West Pharmaceutical Services, Inc. has a 52 week low of $206.19 and a 52 week high of $472.55.
West Pharmaceutical Services (NYSE:WST – Get Rating) last released its earnings results on Thursday, October 27th. The medical instruments supplier reported $2.03 EPS for the quarter, missing the consensus estimate of $2.12 by ($0.09). The company had revenue of $686.90 million for the quarter, compared to analyst estimates of $730.64 million. West Pharmaceutical Services had a net margin of 21.68% and a return on equity of 28.15%. On average, analysts expect that West Pharmaceutical Services, Inc. will post 8.18 EPS for the current fiscal year.
West Pharmaceutical Services Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Wednesday, February 1st. Shareholders of record on Wednesday, January 25th will be paid a dividend of $0.19 per share. The ex-dividend date is Tuesday, January 24th. This represents a $0.76 annualized dividend and a yield of 0.32%. West Pharmaceutical Services’s payout ratio is 9.17%.
Analyst Upgrades and Downgrades
WST has been the topic of a number of research reports. Bank of America cut shares of West Pharmaceutical Services from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $385.00 to $250.00 in a report on Friday, October 28th. KeyCorp dropped their target price on shares of West Pharmaceutical Services from $350.00 to $315.00 and set an “overweight” rating on the stock in a report on Friday, December 2nd. Deutsche Bank Aktiengesellschaft started coverage on shares of West Pharmaceutical Services in a report on Tuesday, December 13th. They issued a “hold” rating and a $250.00 price objective on the stock. UBS Group started coverage on shares of West Pharmaceutical Services in a report on Wednesday, November 30th. They issued a “neutral” rating and a $250.00 price objective on the stock. Finally, StockNews.com started coverage on shares of West Pharmaceutical Services in a report on Wednesday, October 12th. They issued a “hold” rating on the stock. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $266.25.
West Pharmaceutical Services Profile
West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
See Also
Receive News & Ratings for West Pharmaceutical Services Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for West Pharmaceutical Services and related companies with MarketBeat.com’s FREE daily email newsletter.
